Advertisement
Advertisement
PCRX
Pacira BioSciences, Inc. Common Stock
36.43
USDSponsored
+0.01
+0.03%
Nov 06, 15:59 UTC -5
Closed
After-Market
36.43
0.00
0.00%
Pacira BioSciences, Inc. Common Stock (PCRX) Earnings
PCRX Earnings Reports
Positive Surprise Ratio
PCRX beat 28 of 43 last estimates.
65%
Next Report
Date of Next Report
Feb 24, 2027
Estimate for Q4 26 (Revenue/ EPS)
$205.75M
/$0.85
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
+4.51%
/+51.79%
Pacira BioSciences, Inc. Common Stock earnings per share and revenue
On Nov 04, 2026, PCRX reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of 0.74 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 186.28 million, with a --% difference.
Looking ahead to Q4 26, 5 analysts forecast an EPS of 0.85 USD, with revenue projected to reach 205.75 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Xeris Biopharma Holdings, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.02
Actual
$0.06
Surprise
+144.90%
Cronos Group Inc. Common Share
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.03
Actual
$0.04
Surprise
+17.65%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.89
Actual
$1.96
Surprise
+3.17%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.32
Actual
$0.36
Surprise
+9.16%
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.32
Actual
-$0.36
Surprise
-11.15%
Profound Medical Corp. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.18
Actual
-$0.21
Surprise
-11.41%
Akebia Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.03
Actual
-$0.04
Surprise
-6.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.25
Surprise
-40.06%
ZOETIS INC.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.52
Actual
$1.75
Surprise
+14.64%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.38
Surprise
+1.04%
FAQ
What were Pacira BioSciences, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Pacira BioSciences, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Pacira BioSciences, Inc. Common Stock's Q3 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Pacira BioSciences, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 24, 2027.
What are the forecasts for Pacira BioSciences, Inc. Common Stock's next earnings report?
Based on 5
analysts, Pacira BioSciences, Inc. Common Stock is expected to report EPS of $0.85 and revenue of $205.75M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.